Exelixis Inc.

Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference.(Conference news)
Cancer Weekly; 11/17/2009; 1618 words; Exelixis, Inc. (Nasdaq: EXEL) announced that thirteen abstracts related to...the 12:30 pm - 2:30 pm poster session (Abstract #C18) About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the...

News and FDA Updates for China-Biotics (Nasdaq:CHBT), NovaBay (NYSE:NBY), Exelixis (Nasdaq:EXEL).
M2 Presswire; 11/16/2009; 965 words; ...NovaBay (NYSE:NBY), Exelixis (Nasdaq:EXEL)(C...09, China-Biotics, Inc. (Nasdaq:CHBT), a...NovaBay Pharmaceuticals, Inc. (NYSE:NBY), a clinical...2009. On 13/11/09, Exelixis, Inc. (Nasdaq:EXEL) announced...

Ligand Updates License Agreement with Exelixis.
Clinical Trials Week; 11/16/2009; 1442 words; ...amended its license agreement with Exelixis, Inc. (NASDAQ: EXEL) as a result...royalties that may have been payable by Exelixis (see also Ligand Pharmaceuticals...company subsequently acquired by Exelixis. As a result of the amendment...

Exelixis Announces Third Quarter 2009 Financial Results.(Financial report)
Biotech Week; 11/11/2009; 1311 words; Exelixis, Inc. (Nasdaq:EXEL) reported financial...Act of 2008. Net loss attributable to Exelixis, Inc. for the quarter ended September 30...decrease in net loss attributable to Exelixis, Inc. from 2008 to 2009 was primarily due...

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer.
Cancer Weekly; 11/10/2009; 1594 words; Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers...aggressive form of brain cancer (see also Exelixis, Inc.). The data from study XL184-201...Radiology, Therapy, Treatment, Exelixis Inc. This article was prepared by Cancer...